Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes.
Wenaweser P, Pilgrim T, Roth N, Kadner A, Stortecky S, Kalesan B, Meuli F, Büllesfeld L, Khattab AA, Huber C, Eberle B, Erdös G, Meier B, Jüni P, Carrel T, Windecker S. Wenaweser P, et al. Among authors: kalesan b. Am Heart J. 2011 Jun;161(6):1114-24. doi: 10.1016/j.ahj.2011.01.025. Epub 2011 May 11. Am Heart J. 2011. PMID: 21641358
Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. Räber L, et al. Among authors: kalesan b. Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6. Circulation. 2011. PMID: 21646500 Clinical Trial.
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Stefanini GG, et al. Among authors: kalesan b. Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8. Lancet. 2011. PMID: 22075451 Free article. Clinical Trial.
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Räber L, et al. Among authors: kalesan b. Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1. Circulation. 2012. PMID: 22302840
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents.
Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Räber L, Stortecky S, Gloekler S, Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen M, Meier B, Jüni P, Windecker S. Pilgrim T, et al. Among authors: kalesan b. Circ Cardiovasc Interv. 2012 Apr;5(2):202-10. doi: 10.1161/CIRCINTERVENTIONS.111.965749. Epub 2012 Mar 27. Circ Cardiovasc Interv. 2012. PMID: 22456025
118 results